Tetratherix
Tetratherix is an Australian clinical-stage medtech company that licenses products derived from its proprietary Tetramatrix polymer platform for bone regeneration, tissue spacing, surgical healing, and needle-free nasal drug delivery, serving global medical device partners across dental, oncology, and metabolic therapy verticals.
- Company typePublic
- Founded2014
- HeadquartersAlexandria, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tetratherix does
Tetratherix is an Australian clinical-stage medical device company that develops and licenses products derived from its proprietary Tetramatrix platform, a synthetic injectable polymer that forms a three-dimensional matrix upon contact with physiological temperature. The platform enables a portfolio of franchises spanning bone regeneration (Tegenix, TegenEOS for dental and orthopaedic applications), tissue spacing (Tutelix for prostate cancer radiation oncology), tissue healing (TetraDerm for surgical scar reduction), and most recently precision medicine (STEPP, a needle-free nasal delivery technology for GLP-1, peptides, and hormones). The technology is protected by 36 granted patents and the company holds ISO 13485:2016 and FDA CFR 21 Part 820 certifications at its Sydney manufacturing facility.
The company operates a capital-light, partner-centric business model. It develops products through proof-of-concept and clinical trials, then licenses them to leading medical companies while supplying final derivative products for sale and distribution under partners' brands. Confirmed channel and licensing partners include Henry Schein (dental distribution), BioOptix (ophthalmic device development), and Superpower Health Inc. (exclusive 10-year US licence for STEPP generating US$3 million in annual licence payments, up to US$30 million total). Revenue streams therefore comprise licence royalties, product supply income, and milestone payments from partners across multiple geographies.
Tetratherix listed on the ASX (ticker TTX) in June 2025 after raising A$25 million at a market capitalisation of approximately A$145 million, with an estimated A$30 million post-IPO cash balance. The company targets FDA approvals for its bone regeneration franchise by mid-2026 and aims to treat 10 million patients globally by 2035 across an addressable market estimated at US$6.8 billion.
Tetratherix firmographics
Firmographics- Name
- Tetratherix
- Legal name
- Tetratherix Pty Ltd
- Website
- https://tetratherix.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tetratherix is an Australian clinical-stage medtech company that licenses products derived from its proprietary Tetramatrix polymer platform for bone regeneration, tissue spacing, surgical healing, and needle-free nasal drug delivery, serving global medical device partners across dental, oncology, and metabolic therapy verticals.
- Ownership category
- akta.pro rank
Tetratherix industry classification
Industry- Product category
- Regenerative Medicine Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Tetratherix is headquartered
LocationHeadquarters
- HQ city
- Alexandria
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
Tetratherix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing Revenue: The company licenses developed products to leading medical companies and supplies derivative products for partners' sale, distribution, and further development. The 10-year agreement with Superpower Health guarantees US$3 million in annual licence payments.
- Product Supply Revenue: Tetratherix supplies the final derivative products derived from the Tetramatrix platform technology to partners for sale and distribution, creating a steady flow of income from product supply.
- Milestone Payments: Periodic milestone payments from partners at various stages of product development and regulatory approval, similar to 'build-to-buy' model returns.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Tetratherix product offering
Product offeringCore offering
Tetratherix develops and manufactures regenerative medicine medical devices built on its proprietary Tetramatrix™ platform—an injectable biostealth fluid matrix polymer that forms a 3D matrix at body temperature for tissue regeneration and drug delivery. The company commercialises product franchises in bone regeneration, tissue spacing for radiation oncology, surgical tissue healing, and needle-free nasal drug delivery, licensing these products to medical companies and supplying derivative products for partner sale and distribution.
Product overview
Tetratherix is built around the Tetramatrix™ platform technology—the world's first biostealth fluid matrix—which serves as the foundational technology for its entire product portfolio. The platform is a modular biomaterial that is injectable as a fluid and forms a 3D matrix structure upon reaching physiological temperature, enabling tissue regeneration and drug delivery applications. The product portfolio consists of multiple franchises: the Bone Regeneration franchise (Tegenix and TegenEOS), the Tissue Spacing franchise (Tutelix), the Tissue Healing franchise (TetraDerm), and the recently launched Precision Medicine franchise (STEPP needle-free nasal delivery technology). All products are derived from the same core Tetramatrix platform technology.
Differentiator
Problem solved
Functional benefit
Brands
- Tetramatrix: Core platform technology - a synthetic injectable polymer for tissue regeneration with applications in bone healing, surgical spacing, and drug delivery.
- Tegenix
- TegenEOS
- Tutelix
- TetraDerm
- STEPP
Products and services
- Tegenix Tegenix is a bone regeneration product developed using the Tetramatrix platform technology; an innovative carrier designed to be mixed with bone graft materials for dental, oral and orthopaedic applications. Delivered via syringe, it forms a matrix at body temperature providing a stable base for bone graft materials while they integrate with host tissues.
- TegenEOS TegenEOS is a bone regeneration product using Tetramatrix platform technology; a carrier designed to be mixed with bone graft materials for dental, oral and orthopaedic applications, delivered via syringe and forming a matrix at body temperature.
- Tutelix Tutelix is an injectable tissue spacer developed with the Tetramatrix platform technology for radiation oncology applications, particularly prostate cancer. It forms a matrix structure creating space between the prostate and surrounding tissues, is visible under ultrasound and CT-scan imaging, and resorbs over 12 weeks with minimal foreign body reactions.
- TetraDerm TetraDerm is a flowable matrix product developed using the Tetramatrix platform technology for use in surgical incision sites to reduce scarring. Applied during surgery, it provides internal cushioning, reduces mechanical tension and dead space, and physically and biologically integrates with dermal tissue to support natural soft tissue healing with reduced myofibroblast activity.
- STEPP Needle-Free Nasal Delivery STEPP is a proprietary needle-free nasal drug delivery platform using the Tetramatrix polymer as a carrier vehicle that protects and anchors therapeutic molecules in the nasal cavity for controlled absorption into the bloodstream. Designed for delivery of GLP-1 receptor agonists, peptides, hormones, and other biologic compounds.
Quantifiable outcome
- Decreases alpha-smooth muscle actin (a-SMA) to level seen in healthy host tissue in preclinical studies, indicating reduction in myofibroblast activity and scarring
- +4 more outcomes
Companies that use Tetratherix
Customer profileSegments4 records
Ideal customer profiles4 records
Tetratherix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Tetratherix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Superpower Health InccoreExclusive 10-year R&D and licensing agreement with US-based consumer health group Superpower Health Inc worth US$3 million per year (up to US$30M total). Superpower Health will purchase Tetratherix's STEPP needle-free nasal delivery technology for compounds including GLP-1s, peptides, and hormones for the US market. The agreement is immediately revenue-generating and additive to the company's cash position.
- BioOptixminorStrategic partnership established for ophthalmic device development using Tetramatrix platform technology.
- Henry ScheincoreDental distribution partnership with Henry Schein for the distribution of bone regeneration products in dental/oral healthcare markets.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Tetratherix competitors and assessment
Company assessmentDirect peers
- Integra LifeSciences: Established regenerative medicine company selling dermal substitutes, wound matrices, duraplasty products, and orthobiologics. Directly comparable because it competes in the same regenerative scaffold and bone graft substitute categories that Tetratherix's Tetramatrix products target, with similar hospital and specialty channel relationships.
- Organogenesis: Commercial-stage regenerative medicine company focused on wound care and surgical biologics, including skin substitutes and active wound matrices. Directly comparable because both companies develop biologic/biomaterial matrices for wound healing and surgical applications, with Tetratherix's TetraDerm addressing the same clinical problem space.
- Mesoblast: Australian-listed (ASX:MSB) regenerative medicine company developing cellular and tissue engineering therapies for inflammatory and cardiovascular conditions. Directly comparable because it is a listed Australian peer pursuing platform-based regenerative medicine with multiple product candidates and similar regulatory and commercialization hurdles.
- Vericel Corporation: Commercial-stage regenerative medicine company selling cartilage repair (MACI) and burn treatment products. Directly comparable because it operates a similar specialty biologics platform with high-value per-procedure regenerative products sold to specialist surgeons.
- MiMedx Group: Regenerative medicine company focused on placental tissue allografts for wound care and surgical recovery. Comparable because both companies compete in the wound healing and surgical soft tissue regeneration markets with similar clinical positioning around reduced scarring and tissue integration.
Broad incumbents
- Smith+Nephew: Global medical device company with large franchises in advanced wound management and orthopedics. Comparable as a broad incumbent that offers overlapping capabilities in bone grafts and regenerative wound care products as part of a much wider portfolio.
- Stryker Corporation: Major orthopedic medical device company with significant orthobiologics and bone graft substitute portfolios. Comparable as a broad incumbent in the orthopedic bone regeneration space where Tetratherix's Tegenix and TegenEOS products compete for surgeon adoption.
- ConvaTec Group: Global medical products company with established advanced wound care and regenerative tissue franchises. Comparable as a broad incumbent competing in the same wound healing and tissue regeneration categories that Tetramatrix-based products target.
Emerging players
- OptiNose: Specialty pharmaceutical company developing nasal drug delivery technology for neurological and respiratory conditions. Comparable as an emerging player in nasal drug delivery, the same category where Tetratherix's STEPP technology is positioned for GLP-1 and peptide delivery.
- Bone Therapeutics: Cellular therapy company developing regenerative bone and cartilage treatments. Comparable as an emerging player in bone regeneration, sharing Tetratherix's focus on musculoskeletal tissue repair but using a different (cell-based) technology platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Tetratherix social profiles
Digital presenceTetratherix compliance and trust
Trust signalCompliance2 records
Tetratherix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tetratherix leadership team
Management profileNumber of profiles
Profiles10 records
Tetratherix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tetratherix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tetratherix
What does Tetratherix do?
Tetratherix develops and manufactures regenerative medicine medical devices built on its proprietary Tetramatrix™ platform—an injectable biostealth fluid matrix polymer that forms a 3D matrix at body temperature for tissue regeneration and drug delivery. The company commercialises product franchises in bone regeneration, tissue spacing for radiation oncology, surgical tissue healing, and needle-free nasal drug delivery, licensing these products to medical companies and supplying derivative products for partner sale and distribution.
Is Tetratherix a public or private company?
Tetratherix is a public company. It is classified as public and is currently operating.
When was Tetratherix founded?
Tetratherix was founded in 2014. It employs 11 to 50 people.
Where is Tetratherix based?
Tetratherix is headquartered in Alexandria, Australia, in the Oceania region.
How does Tetratherix make money?
Three revenue lines are on record. Licensing Revenue is the primary driver. The others are product Supply Revenue and milestone Payments.
Who are Tetratherix's main competitors?
Direct peers on record are Integra LifeSciences, Organogenesis, Mesoblast, Vericel Corporation and MiMedx Group. Broad incumbents are Smith+Nephew, Stryker Corporation and ConvaTec Group. Emerging players are OptiNose and Bone Therapeutics.
Does Tetratherix have an API?
No public API is recorded for Tetratherix.
What industry is Tetratherix in?
Tetratherix's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.